ATE424189T1 - Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker - Google Patents

Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker

Info

Publication number
ATE424189T1
ATE424189T1 AT05792891T AT05792891T ATE424189T1 AT E424189 T1 ATE424189 T1 AT E424189T1 AT 05792891 T AT05792891 T AT 05792891T AT 05792891 T AT05792891 T AT 05792891T AT E424189 T1 ATE424189 T1 AT E424189T1
Authority
AT
Austria
Prior art keywords
amino
hydroxybenzoic acid
reducing sugar
compositions containing
lactose
Prior art date
Application number
AT05792891T
Other languages
English (en)
Inventor
Matt Kaczanowski
Thomas Williams
Kurt Trombley
Nancy Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35832068&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE424189T1 publication Critical patent/ATE424189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pyrrole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT05792891T 2004-09-01 2005-08-31 Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker ATE424189T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60638604P 2004-09-01 2004-09-01

Publications (1)

Publication Number Publication Date
ATE424189T1 true ATE424189T1 (de) 2009-03-15

Family

ID=35832068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05792891T ATE424189T1 (de) 2004-09-01 2005-08-31 Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker

Country Status (13)

Country Link
US (2) US20060046973A1 (de)
EP (1) EP1784166B1 (de)
JP (1) JP2008511658A (de)
KR (3) KR20080085924A (de)
CN (1) CN101010069B (de)
AT (1) ATE424189T1 (de)
BR (1) BRPI0514827A (de)
CA (1) CA2578714C (de)
DE (1) DE602005013098D1 (de)
ES (1) ES2323536T3 (de)
IL (1) IL181456A (de)
MX (1) MX2007002443A (de)
WO (1) WO2006028831A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
FR2964099B1 (fr) * 2010-08-30 2012-08-17 Saint Gobain Isover Composition d'encollage pour laine minerale comprenant un sucre non reducteur et un sel metallique d'acide inorganique, et produits isolants obtenus.
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US20160045442A1 (en) * 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US5514676A (en) * 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
JPH0334929A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与用組成物
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
ES2078509T3 (es) * 1990-02-19 1995-12-16 Senju Pharma Co Composiciones inhibidoras de la reaccion de maillard.
US5114003A (en) * 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
JPH1015032A (ja) * 1996-06-27 1998-01-20 Nisshin Flour Milling Co Ltd 安定化された５−アミノサリチル酸固形製剤
DK1441700T3 (da) * 2001-10-15 2007-10-08 Ferring Bv Fremgangsmåde til fremstilling af en farmaceutisk sammensætning omfattende 5-aminosalicylsyre til anvendelse ved behandling af ulcerativ colitis og Crohn's sygdom
MXPA04004747A (es) * 2001-11-23 2004-08-02 Procter & Gamble Forma de dosificacion farmaceutica con multiples recubrimientos.

Also Published As

Publication number Publication date
KR101123001B1 (ko) 2012-03-13
KR20080085924A (ko) 2008-09-24
EP1784166A2 (de) 2007-05-16
WO2006028831A2 (en) 2006-03-16
KR20100031140A (ko) 2010-03-19
KR20070045291A (ko) 2007-05-02
MX2007002443A (es) 2007-05-04
WO2006028831A3 (en) 2006-06-01
US20060046973A1 (en) 2006-03-02
CA2578714A1 (en) 2006-03-16
IL181456A (en) 2015-04-30
CN101010069B (zh) 2011-11-23
BRPI0514827A (pt) 2008-06-24
KR100882756B1 (ko) 2009-02-09
CA2578714C (en) 2011-05-03
JP2008511658A (ja) 2008-04-17
DE602005013098D1 (de) 2009-04-16
IL181456A0 (en) 2007-07-04
US20100210605A1 (en) 2010-08-19
CN101010069A (zh) 2007-08-01
EP1784166B1 (de) 2009-03-04
ES2323536T3 (es) 2009-07-20

Similar Documents

Publication Publication Date Title
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
NO20084882L (no) Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA200900351A1 (ru) Ингибиторы тирозинкиназы брутона
ATE362314T1 (de) Herbizidzusammensetzungen umfassend imidazolinonsäure
DK1890681T3 (da) Törgranuleret sammensætning indeholdende emtricitabin og tenofovir DF
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
MEP25008A (en) Topical methadone compositions and methods for using the same
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
EA200702594A1 (ru) Многофункциональные композиции концентрата с высоким содержанием действующего вещества для контроля эктопаразитов
WO2006060515A3 (en) System for improved percutaneous absorption of skin benefiting agents
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
ATE424189T1 (de) Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker
WO2019202399A8 (en) Antibodies for chelated radionuclides and clearing agents
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
WO2006102004A3 (en) A stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
EA200702496A1 (ru) Местная композиция, содержащая желатин

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties